Answers are grounded in this paper and cite their sources.
Case report shows improvement in systemic lupus erythematosus while reducing immunosuppressants, suggesting a new treatment approach.
BACKGROUND/AIM: ), a selective antioxidant with anti-inflammatory properties, may serve as an adjunct therapy, potentially maintaining disease control while reducing immunosuppressive burden. CASE REPORT: capsule therapy was initiated as an adjunct. The patient exhibited rapid and robust serologic improvement, allowing for the complete discontinuation of mycophenolic acid within one month. Over an extended follow-up through early 2026, her regimen was successfully de-escalated to a minimized monotherapy of prednisolone 10 mg/day. Her anti-dsDNA levels stabilized within a strictly normal range (<15 IU/ml), with normalized complement levels, no further infections, and profoundly reduced fatigue. Flow-cytometric profiling revealed a coordinated reprogramming of adaptive immunity toward a controlled, non-senescent state, including a homeostatic reset in the B-cell compartment and decreased active-disease-associated T cells. CONCLUSION: Adjuvant molecular hydrogen therapy stabilized active SLE, enabling substantial reduction of conventional immunosuppressants while maintaining durable clinical and serologic remission. This strategy may represent a promising immunosuppressant-sparing approach and warrants validation in controlled trials.
No takes yet. Share an insight, caveat, or question.
LIN et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: